CClinicalTrials.gg
RecruitingNCT06103903MARKSUpdated Oct 27, 2023

Measure of Acceptance of chRonic Visible sKin conditionS

An observational study in Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance and Psychological Well-Being, sponsored by University Hospital, Tours. Recruiting at 1 site in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by University Hospital, Tours · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 9 months later.
Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
250
Ages
6 Years and older
Sex
All
01

Study summary

The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients (children, adolescents, adults) and their parents (depending on the composition of the family cluster), in a multicentric manner (for territorial representativeness).

Read the detailed description

The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients (children, adolescents, adults) and their parents (depending on the composition of the family cluster), in a multicentric manner (for territorial representativeness).

The investigator will screen the patients and give them a link to complete the questionnaire (according to the age), that includes a pre-scale of acceptation of 50-55 items.

02

Conditions studied

  • Acceptance of Visible Chronic Dermatological Disease
  • Disease Acceptance
  • Psychological Well-Being
  • Social Segregation

Browse trials for

Keywords

  • Chronic dermatological disease
  • Psychology
  • Sociology
  • Disease Acceptance
  • Vitiligo
  • port wine stain
  • hyperpigmentation
  • alopecia areata
03

In context

Skin Diseases

538 studies on the registry are indexed under Skin Diseases; 92 are open to participants now.

This study's planned enrollment of 250 is above the median of 168 across 147 observational studies indexed under Skin Diseases.

Browse Skin Diseases studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 304 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with visible chronic dermatological diseases and their family circle

Inclusion criteria

  1. Targeted pathologies:

    • Flat angioma
    • Primary hypopigmentation and early vitiligo
    • Primary hyperpigmentation
    • Refractory alopecia areata or congenital alopecia
  2. Persons concerned:

    • Children (≥ 6 years old) suffering from one of the aforementioned pathologies
    • Adults suffering from one of the above-mentioned pathologies
    • Parents of children suffering from one of the aforementioned pathologies
    • Parents of young adult patients if they live under the same roof
  3. Oral agreement for each person (major/minor) and, where applicable, one of the holders of parental authority (minor)

Exclusion criteria

Exclusion Criteria:

  1. Secondary "marks" (post-inflammatory, post-medication, post-traumatic, etc.)
  2. Major psychiatric disorders
05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children aged 6-13 years

    Children aged 6-13 years with a chronic skin visible disease

    Behavioral: Questionnaire

  • Adolescents aged 14-17 years

    Adolescents aged 14-17 years years with a chronic skin visible disease

    Behavioral: Questionnaire

  • Adult patients

    Adult patients aged 18 years and more with a chronic skin visible disease

    Behavioral: Questionnaire

  • Parents of children aged 6 years and more

    Parents of children aged 6 years and more with a chronic skin visible disease

    Behavioral: Questionnaire

Interventions

  • BehavioralQuestionnaire

    Questionnaire according to age (6-13;14-17); the parents for minors and adults

06

What researchers measure

Primary outcomes

  1. Questionnaire analysis

    Analysis of responses to the 4 questionnaires (scales) evaluating the acceptance of chronic dermatological diseases visible in children, adolescents, adults and parents, respectively.

    Time frame: Up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06103903
Lead sponsor
University Hospital, Tours
Collaborators
INSERM UMR 1246 SPHERE
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Jan 1, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Oct 27, 2023

Study contacts

Annabel MARUANI, MD-PhD
Contact
annabel.maruani@univ-tours.fr
+33 (0)247479076
Annabel MARUANI, MD-PhD
study director · University Hospital of TOURS
Jean-Benoit HARDOUIN, MD-PhD
study chair · INSERM UMR 1246 SPHERE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion